Curt Hartman - Chair of the Board, President, Chief Executive Officer Todd Garner - Executive Vice President, Chief Financial Officer.

Good afternoon, everyone. Before the conference call begins, let me remind you that during this call management will be making comments and statements regarding its financial outlook, its plans and objectives.

These statements represent the forward-looking statements that involve risks and uncertainties as those terms are defined under the Federal Securities Laws. Investors are cautioned that any such forward-looking statements are not guarantees for future events, performance or results.

The company's actual results may differ materially from its current expectations. Please refer to the risks and other uncertainties disclosed under the forward-looking information in today's press release, as well as the company's SEC filings for more details on the risks and uncertainties that may cause actual results to differ materially.

The company disclaims any obligation to update any forward-looking statements that may be discussed during this call, except as may be required by applicable law. You will also hear management refer to non-GAAP or adjusted measurements during this discussion.

While these figures are not a substitute for GAAP measurements, management uses these figures to aid in monitoring the company's ongoing financial performances from quarter-to-quarter and year-to-year on a regular basis and for the benchmarking against other medical technology companies.

Adjusted net income and adjusted earnings from share measure the income of the company, excluding credits or charges that are considered by the company to be special or outside of its normal ongoing operation. These adjusting items are specified in the reconciliations supporting the company's earnings releases posted to the company's website.

With these required announcements completed, I will turn the call over to Curt Hartman, CONMED's Chair of the Board, President and Chief Executive Officer for opening remarks. Mr. Hartman, please go ahead. .

Thank you, Lisa. Good afternoon and thank you for joining us for CONMED’s third quarter 2022 earnings call. I’m joined by Todd Garner, Executive Vice President and Chief Financial Officer. Today we will walk you through our third quarter results and our full year outlook. We will then open the call to your questions.

Turning to our results, total sales for the third quarter were $275.1 million, representing a year-over-year increase of 10.6% as reported and an increase of 12.1% in constant currency versus the same quarter in 2021. From an earnings perspective during the third quarter, our GAAP net income totaled $46.1 million.

This compares to net income of $14.9 million in the third quarter of 2021. Excluding special items that affected comparability, our adjusted net income was $23.8 million, a decline of 3.7% versus the prior year's third quarter and our adjusted diluted net earnings per share came in at $0.77, a decline of 3.8% versus the prior year's third quarter.

Looking at the quarter in more detail, the international markets delivered solid results with 9.6% constant currency growth, while the domestic business grew 14.2% reported. With that said, the industry continues to face headwinds.

From my perspective, the two largest issues remain less than ideal healthcare staffing levels and ongoing global supply chain inconsistencies. These issues did not worsen in the third quarter, but we saw only marginal improvement compared to the second quarter.

From a sales run rate perspective, the quarter started slowly and while the September run rate improved, that recovery was not strong enough to achieve our double digit growth outlook on the top line. Regarding the acquisitions, our first full quarter with In2Bones was very positive and we remain excited about this business.

Additionally, we are incredibly pleased to announce and close on the Biorez acquisition in August. We quickly embraced this business and our laser focused and progressing clinical study work, training the sales force and educating our customers on the product. On this last point, I personally attended a large customer event during September.

If this meeting was an early indication of customers’ enthusiasm for the concept of healing, then our instincts on the BioBrace technology will be well justified in the years ahead. I'll wrap up my comments with a mention of a non-financial goal.

I'm proud to announce that CONMED recently published its first ESG Sustainability Report, which can be found on our website. This report is the work product of a global cross functional team within CONMED, supported by an external third party expert. Importantly, all of the information in our report has been validated by our audit group.

This report will serve as our baseline as we responsibly pursue enhancements to our ESG initiatives across CONMED. I want to thank the CONMED team responsible for this effort. In closing, I'm proud of the CONMED team and the progress we've made both for the short term and the long term outlook of the company.

With three quarters of 2022 behind us, we have delivered strong constant currency organic growth and have closed on two high growth, high margin acquisitions that have further strengthened our outlook for the future, while continuing to navigate the challenging global market.

The CONMED Global leadership team and our organization around the world continue to perform exceptionally well in an unpredictable environment. I'll now turn the call over to Todd, who will provide a more detailed analysis of our financial performance and walk you through outlook. Todd. .

Thank you, Curt. All sales growth numbers I reference today will be given in constant currency. The reconciliation to GAAP numbers is included in our press release. As usual, we have included an investor deck on our website that summarizes the results of the quarter and our updated guidance.

For the third quarter of 2022, our total sales increased 12.1%. Revenue from the recent acquisitions was $10.3 million in the quarter, putting our global organic growth for Q3 at 7.9%. For Q3, our sales in the U.S. increased 14.2% versus the prior year quarter. Our international sales grew 9.6% for the quarter compared to Q3 2021.

Worldwide, orthopedics revenue grew 14.0% in the third quarter. In the U.S. orthopedic sales grew 20.4% and internationally orthopedic sales increased 10.4%. Total worldwide general surgery revenue increased 10.7% in the quarter. U.S. general surgery revenue grew 11.8%, internationally general surgery revenue increased 8.5%.

Now, let's move to the expense side of the income statement. We will discuss expenses and profitability in the third quarter, excluding special items which include charges for acquisitions, debt refinancing costs, amortization of intangible assets and amortization of deferred financing fees and debt discount net of tax.

Adjusted gross margin for the third quarter was 55.9%, a decrease of 130 basis points from the prior year quarter. Last quarter, I said to expect gross margins around 55% for the back half of 2022. In Q3 some mix issues, including lower capital sales caused a stronger than expected gross margin.

We think some of that mix may swing back the other way in Q4 and the increased currency headwind will impact Q4 margins. With these dynamics Q4 gross margins could end up below 55%. Research and development expense for the third quarter was 4.6% of sales, 20 basis points higher than the prior year quarter.

Third quarter adjusted SGA expenses were 37.7% of sales, a decrease of 170 basis points from Q3, 2021. We are getting the returns on our sales force expansion from last summer and expect those returns to increase over the coming quarters. Specifically in Q4 we would expect adjusted SGA expense to be between 35.5% and 36.0% of sales.

On an adjusted basis interest expense was $7.0 million in the third quarter. We expect interest expense in the coming quarters to be $7.5 million or more depending on future federal reserve decisions. The adjusted effective tax rate was 24.9% in Q3, and we think 25% is the right expectation going forward.

Third quarter GAAP net income was $46.2 million. This compares to GAAP net income of $14.9 million in Q3 of 2021. GAAP earnings per diluted share were $1.48 this quarter compared to $0.47 a year ago.

Excluding the impact of special items discussed earlier, we reported adjusted net income of $23.8 million, a decrease of 3.7% compared to the third quarter of 2021. Our Q3 adjusted diluted net earnings per share was $0.77, a decrease of 3.8% compared to the prior year quarter.

Turning to the balance sheet, our cash balance at the end of the quarter was $33.4 million compared to $53.2 million dollars as of June 30. Accounts receivable days as of September 30 were 65 days compared to 64 at the end of Q2. Inventory days at quarter end were 222 compared to 192 at June 30.

Nine days of the increase is related to the inventory from the recent acquisitions. The remaining increase is due to building inventory to mitigate supply chain challenges. Long term debt at the end of the quarter was $1.036 billion versus $982 million as of June 30. The change is due to the acquisition of Biorez during the quarter.

Our leverage ratio on September 30, 2022 was 5.0x compared to 4.7x on June 30. Cash flow provided from operations for the quarter was $25.9 million compared to $21.4 million in the third quarter of 2021. Capital expenditures in the third quarter were $6.7 million, compared to $5.6 million dollars a year ago. Now, let's turn to financial guidance.

We expect reported revenue in Q4 to be between $305 million and $320 million. This includes increased currency headwinds of 300 to 350 basis points for Q4 alone. For the full year 2022 we now estimate the currency headwind to revenue to be between 150 and 180 basis points and reported revenue to be between $1.1 billion and $1.115 billion.

This updated revenue guidance translates to organic growth between 11% and 16% in Q4 and between 8% and 9% for the full year. We've included the detail of the different components of our financial guidance in the investor deck associated with this call, which can be found on our website. We expect adjusted EPS in Q4 between $0.98 and $1.05.

That makes our full year 2022 adjusted EPS guidance range between $3.21 and $3.28. The reduction to the full year range from last quarter is due to the decrease in the potential upside in revenue we anticipated 90 days ago. We now expect the procedure growth to be more moderate than we did a quarter ago and hospital staffing remains a challenge.

Inflation and currency are hindering our ability to offset the reductions to revenue. We will talk about our 2023 guidance in January, but we can already see that the recent significant strengthening of the U.S. dollar will create a meaningful currency headwind for 2023.

Given the multiple moving factors involved in the calculation, it is difficult to accurately project, but our current estimates are that the impact could now be around $0.30. Obviously as we put the 2023 plan together, we will be looking for ways to mitigate this headwind as much as possible.

We feel very good about the exciting revenue growth potential from the portfolio we have built, including our recent acquisitions. We are keeping the engines strong while being responsive to the dynamics in the marketplace.

When the cost challenges subside and they will at some point, we are excited about the profitability this improved growth and margin engine can provide. And with that, we'd like to open it up to your questions and I'll hand it back to Lisa. .

Thank you. [Operator Instructions]. Thank you. At this time we are bringing to the platform, M. Matson from Needham. Please go ahead, your line is open. .

Yeah, thanks for taking my questions. I guess I'll just start with the currency. You know the $0.30 headwind, it seems like it's quite a bit bigger. I thought that Todd said that it would be kind of like $0.10 back in mid-September. I know that the dollars continue to strengthen quite a bit, but just curious about kind of the difference there.

Sorry, for 2023 that is, just to be clear. .

Yeah, sure Mike. Yes, so through the summer we had run that analysis and you're right, in early September, which was actually based on you know rates in the summer, we had estimated about $0.10. Obviously the currency has moved quite a bit since then, and that's what's driven to change. .

Okay. And just in terms of the revenue kind of shortfall that you're talking about, you know how confident are you that it's really driven by kind of just overall procedure growth, market growth, as opposed to some market share, competitive dynamics or something like that. .

Yeah, I think – you know I look at the detail in our press release and our consumable volume was very strong in the quarter relative to prior year. So we feel like we're getting our share of the procedures. Obviously we did not have a good capital quarter. We’ve not had a great capital year.

Some of that has been supply chain constraints, some of that has been the age of our capital, some of that has just been ongoing enhancements to the capital we have in the market. So I really think that there's good volume in the marketplace. Again, better staffing would help that.

I recently read an article that even staffing levels at the small town hospitals are slowing things down. Never mind the big centers, but fighting through that is I think what facilities are doing and companies are trying to do their best to help them. So I feel good about our overall business, I feel good about the composition of our product mix.

We've got new products hitting the market as well. So I don't see any indications that we're losing share at this point in time, and I guess if I did I would point to capital right now as a one spot where we may be a little suspect given the age of the portfolio. .

Okay, got it. Thank you. .

Thank you. Our next question will be coming from Young Li of Jefferies. One moment, please. Your line is open. .

All right.

Hey guys, can you hear me alright?.

Yes, we can. .

All right, great. Thanks so much for the questions. I guess to start, was wondering, you know it seems like AirSeal, Buffalo Filter are continuing to grow 20% plus, so it's pretty encouraging. Can you maybe talk a little bit more about the business performance during the quarter, and if you can comment on the OEM part, that would be helpful as well. .

New Jersey, New York and Texas, and interestingly that would represent 18% of the population, about 15% of the hospital. So with three additional states, we could see the number and percentage of the population, percentage of hospitals effectively double, and then there's approximately seven that are on deck for 2024.

So there is good momentum in the legislative side; there's good momentum as procedures have recovered, and those things all help serve and grow the smoke business. .

Okay, great, I really appreciate the color. I guess for my follow-up, just kind of want to level set some consensus expectations for next year. I think In2Bones has around $43 million and before for Biorez you mentioned mid-single digits in 2023. You know it sounds like the initial interest is pretty high.

So if you can maybe comment about those type of consensus expectations, if they are in the right place?.

Yes, I'm not going to talk about consensus Young, but I will talk about what we've said, right? What we've said is that with In2Bones, we said that that market was growing in the high single digits, and that business was growing at least twice that, and it has certainly done that since we’ve owned it.

So it’s off to a very good start and doing very well. And then you’re right, on Biorez we said that 2023 should be single digit millions in revenue and then in 2024 we would get to double digit millions in revenue. So that's what we've said and I'm not going to, I'm not going to grade consensus here with you today. .

Okay, fair enough. Thanks so much. .

Thank you. One moment for the next question. The next question we have is coming from Robbie Marcus of J.P. Morgan. Please go head. .

Yes, hi! Thanks for taking the questions. Maybe first, you know it does look like capital was the bad guy here. That's the one that missed pretty significantly versus consensus. You know capital is not the best environment, but we are seeing different trends from companies out there. You talk about some of this is backlogs.

Maybe you could just kind of put some of the pieces together as how much is a weak capital environment? How much is not having enough supply due to backlog and how much is that backlog? And do you expect it to pick up anytime soon. .

Yes, I think anything that's related to electronic circuit boards, you're going to see delays and we have an energy platform that sold on the general surgery side that is not immune to those challenges and that is not a new problem.

But getting those supplies through the chain into production has been more delayed than we might have originally assumed. We've made some progress on some of the products, but we have others that we're still working our way through those electronics and supply chain issues.

As I mentioned earlier in one of the other sections, some of our capital is a little bit dated and we need to refresh that and get that into the marketplace, that always place with capital results. New capital sells better. It's got better features, better benefits and so we're working on those next generation platforms. So it's a combination of both.

I got to be honest with you; I don't think we have seen any drop in appetite for capital from our customers as procedure volumes have increased relative to what they might have been in the past 12, previous 12 months.

People are buying the capital that they need to do the procedures and every capital item we sell that has to be in the room to do the procedure. So I don't think we've yet felt a slowdown by our customer base on capital acquisition interests. .

Great! Maybe Todd, as we think about that $0.30 for next year on EPS, I believe you also have some floating rate debt as well. So first on the FX component, you know that's a bigger drop through, 10% or so than we would normally see from CONMED. Maybe you could walk us through.

Is it a function of the hedges or what exactly is going on there? And at current interest rates and assuming I believe we're at 50 bips heading into the year and maybe 25 bips in the beginning of next year, how should we be thinking about the interest expense for 2020. .

Sure. Yeah, so the hedge is basically defer the cost right.

Their job is to protect the near term and take volatility out of the near term, but at some point those bills come due, and so I think because almost half of our business is outside the United States and because we do hedge essentially everywhere that we do business, I think we do have a little more exposure on a relative basis to that than others.

And so as the currency has moved here in the last few months and then especially very recently, you know that is, that increases the mass of what bill says is going to be coming due right. Now, obviously the answer will be different than that, because rates will move, mix will move.

You know it’s very dependent on what we sell and what we spend, in what geography and then of course what rates do.

And so it's very difficult to project with precision, but I did want to kind of get everybody in the ballpark of where the math says we are today, because we do have a I think a more comprehensive hedging program than a lot of the names that you spend time on.

And so there is a little – we've been more protected in 2022 than others, and that pain has been deferred a little bit to 2023, which is the job of the hedges, it's what they do. Let me pause there Robbie, on that before I go to interest expense. .

And just confirm, you run it through sales, right? So that's where we'll see the impact as it falls through the P&L?.

We have both revenue and cost hedges, so it's – it kind of shows up throughout the P&L. On interest expense, you know what I said for Q4, the $7.5 million that's based on current rates, so that's a quarterly number. You know we expect the debt to come down right as we pay down debt, but I can't tell you what interest rates are going to do.

I think obviously the consensus is that they are probably going to go up. And so what I've told you is that Q4 should be at least $7.5 million. We’ll have to see what the fed does at the next meeting and that will affect the coming quarters. .

And if I could sneak one last one in, you know I think people are just a little concerned on the organic sales miss versus expectations. Are you sure that it's more of a market issue rather than a share issue or anything else we should be thinking about there in third quarter and going forward. Thanks a lot. .

Yeah, obviously we pay pretty close attention to our business and where the opportunities are and where we perhaps have lost opportunities or picked up opportunities. And as I said, the July-August performance was slow. It just was slow for our mix of businesses.

Things improved dramatically in the month of September, but not enough to close the gap, and then obviously we didn't close the capital that we needed to close to secure the quarter. So I don't feel like that in the 90 day window we suddenly started losing market share, so I feel pretty good about where we're at. .

Great! Thanks a lot. .

Thank you. One moment for our next question. And our next question is coming from Matthew Mishan of KeyBanc. Please go head. .

Hey! Good afternoon and thank you for taking the questions. I just wanted to follow up on the age of the capital, and just which capital are you kind of referring to, because if you're referring to a potential refresh of like AirSeal and like Buffalo Filter, I think that's like a very exciting, potentially into next year or the year after.

Are we talking about like the powered instruments and like surgical visualization, stuff that's a little bit more of like legacy CONMED?.

Well, I think certainly the legacy CONMED items that you discussed, the power tools, if you look at the entry date to the market on those, they are probably coming up in that window where refresh or additions expansions would be in our not too distant future.

As far as AirSeal goes, the AirSeal platform, the AirSeal box is obviously a very important component of our overall growth story, and I think everybody should assume that whether it's the consumables or the capital, those remain under development and new items, new features coming all the time.

Again, I think everybody on the call knows we don't talk about timing on new products to market. We prefer to get them in the market before we talk about them and we're going to stay true to that approach. .

And on Biorez, like just to follow-up to like the previous one where you guys don't really talk about like new product development and how that – how are you going to talk about like Biorez moving forward as like you're developing like that platform.

Are you going to specifically call out numbers once you get past like the initial M&A phase of it, and as it becomes organic, I'm just curious how you how you're thinking about communicating that platform moving forward?.

I think we'll do what we've always done, once it becomes organic, it will fit into the orthopedics category. I'm sure we'll make non-financial commentary relative to it.

We’ll be clearly talking about studies as they come to fruition and close and further impact the results, but we're not going to - we're not going to break out Biorez or In2Bones as individual line items at every call. .

Okay, and if I could squeeze just one more in. I think obviously with the leverage, free cash flow is going to become pretty important going into next year.

Just, as you think about the assumptions of free cash flow for this year, how should we be thinking about it, and then just so I guess any major moving pieces you're thinking around free cash flow without having to give guidance for next year. .

Sure, Matt. You know I think twenty 2022 has been tough because of the inventory, right. Trying to stock up to mitigate the supply chain issues has put a dent in our free cash flow because of the working capital increases.

I would expect that as we go to 2023, you know that is more neutralized and so you should get – we should get back to free cash flow traveling closer to net income as we've traditionally been. So this is – 2022 has been the one-off year where we've invested a lot in working capital.

I think you know intelligently and strategically to try and make sure we could service our customers in a very difficult supply chain environment. But the hope is that we've got those inventory levels at a place where you know they can be relatively stable and that free cash flow should tie closer to net income as we move forward. .

Thanks Todd. .

Thank you. And for our next question, one moment please. Our next question will be coming from Matt O'Brien of Piper Sandler. Please go ahead. .

Thanks for taking the question. You know as I look at the, what you said as far as growth of In2Bones and Biorez or contribution to the acquisitions, I think you said 220 basis points. I think that's about $10.5 million. I'm assuming a majority of that is In2Bones at this point. I don't think we're expecting much out of Biorez.

So is that math about right to you? It seems like in2Bones is running a little bit ahead of what you guys are kind of contemplating when you did that deal, and would just love to hear you know what exactly you're seeing there from a momentum perspective in that category?.

Yes, so on the pure math, you're right. I mean, the lion's share of that is In2Bones. Biorez is just getting started, so very pleased with both of them, but In2Bones is by far the revenue contributor at this point. .

And I think Matt, in terms of the marketplace reaction with In2Bones, I think when we originally did the deal, we guided to $20 million in the back half. Obviously it's going to be more than that, because we closed before the end of the second quarter.

But I think we've also increased our expectations here for the remainder of the year based on what has happened and based on how that business trends. There is a strong fourth quarter push in foot and ankle and we've also been – candidly some of the things we saw in diligence were even better than we thought.

We’re very excited by the work that they are doing with their quantum ankle. We're very excited by a launch of a new product that's just hitting the market, some carbon plating that's got some unique features and benefits; very early days on that, but enthusiasm, early enthusiasm.

And then just [inaudible] the sales force, I mean we bought a complete stand-alone business and we've been very pleased with the sales force and their commitment, their commitment under CONMED’s ownership. You know that's always a risk when you have a transaction.

Sales forces are you know very suspect of transactions and this sales force has settled right in and really done a nice job for us, and we're very pleased overall with the team and we're ramping up in the international markets. A very small contribution at this point in time in international.

Part of what CONMED brings to that story is the international approval pathway, the RAQA work that needs to be done to get those approvals. We’re suited for that work. We have the staff, the resources to do that work. So everything that we had seen in diligence has come to fruition.

Haven't really run into any negative surprises and really pleased with the depth of experience that the leadership team brings to CONMED across the foot and ankle space. .

Okay, that's great to hear. And then the follow up question is, just you know you've got this extra currency headwind; you've got more interesting expense you're going to be facing for ‘23. How do you balance you know investing for growth in SmokePlus [ph].

You know these acquisitions versus profitability and I guess asked directly and I'm not sure to how you can answer this, but can you grow earnings next year given all of these headwinds?.

Well look, we're going to talk about 2023 in January. But we've got a very strong revenue growth line, right, and so we'll be focused on fueling that and making sure that that stays strong. The cost environment, the macro environment is challenging and has been challenging for longer than any of us are happy about.

We believe strongly the way out of this is growth, right, and so we have made the conscious decision to maintain the engine, not cut resources more deeply than we already have, and be able to service our customers and do the best we can on the revenue line, and then you know that will provide the room in the P&L to drop profitability through the bottom.

As you've said, you know interest – we’ve talked about the acquisitions. They are still dilutive into 2023 before they get accretive in 2024 and so we got to finish digesting those. And right now currency is a stiffer headwind than we thought a few months ago.

That can change the other way, right, and so we'll have to see how all of that shakes out as we put the final plan together and we talk to you about 2023 in January. .

Got it. Thank you..

Thank you. One moment while we prepare for the next question. We have the next question coming from Rick Wise of Stifel. Please go ahead, your line is open. .

Good afternoon to you both. Todd, I was struck by, I think you said it, maybe Curt said it, talking about the sales force, talking about SG&A, you said we're starting to get returns or better returns on your sales investment.

Knowing how significantly you expanded the sales force, I think maybe twice over the last couple of years, I was hoping you could expand on those comments. When you use the word returns, are you – are we seeing – are you seeing more new account opening going deeper in existing accounts.

What part of the business is benefiting, and again this isn't a request for guidance or more. How has that set you up for the potential, the possibility of maybe more meaningful or significant operating sales or operating leverage as we look ahead to ’23. .

Yeah your right Rick, it was me. And it is a returns, it was a returns comment, which is basically we made significant sales force expansions last summer, believing that volumes were about to come back in a strong way.

Obviously, we all know that because Delta and Omicron, the volumes have been delayed and were not like we all thought they would be at the time. And so it took longer than it normally does for those new sales reps to get the customer facing time and experience to be productive and to start paying back.

And so – but we are now, a year later, so it's taken longer than it normally would, but just based on deleverage right, SG&A as a percentage of sales, which has been – which was higher as we digested those investments, you now see that we are lower than the prior year and so that we are getting the returns basically on those additional resources.

And so I think we're – in hindsight, did we do it a couple of quarters early, yeah probably, because, none of us knew what was going to happen at the end of last year.

But we're very happy with the decisions we made and the investments we made and those teams are often running and being productive now and we expect that they will only get more productive in the coming quarters. .

Got you.

And I guess the next thing I'd say, at a high level Curt, as you think about ’23, ’24, I'm just wondering how in your own mind, you know if you had to say now, how do you think the recovery based on what you know for your business, how is it going to unfold? I did a 150 doc survey recently and the majority of the doctors saying that staffing is going to be a headwind through much of ’23.

It’s going to get better they think in the second half, but they sort of, and I'm summarizing their counts. They basically said ’24 is going to be the first time where they feel like they're going to have worked through a lot of the staffing issues.

Is that the way you're seeing? Is that the way you're planning, and is the set up for next year sort of a softer first half, again, aside from currency.

Softer first half and acceleration through the second half into ’24, is that the way you're thinking about?.

I don't think I would believe that surgical staff levels, even broadly speaking health care staffing levels are going to improve overnight. I think this is something that's going to be measured in quarters, if not to your comment into 2024.

There is a lot that has to happen to get back to those fully staffed levels, and there are some very well-known institutions doing some very dramatic things to try to navigate the current staff challenges and I think there are other factors at play as well.

We're coming into seasonal flu and who knows what will happen with COVID and childhood respiratory disease and how that puts burdens on health system. So there's so many other factors that go into that question Rick. It's a little hard to predict, but the one thing I am confident of, it will not be solved overnight. It's going to take some time.

With that said, when I look at our portfolio, whether it's the recent acquisitions of In2Bones or Biorez, both we believe will be high growth assets with great gross margins or I look at existing portfolio, products that CONMED has, whether it's AirSeal, Buffalo Filter are recently released in 2022, Argo, Anchor or the ClickLok portfolio.

Those items are all high gross margin items. Our consumable volume was very strong really throughout the first three quarters of this year and we can just continue to build on that with organic innovation as well. We'll do everything possible that we control and let the market sort out those other macro factors.

You know when we go to January we'll give more outlook views on 2023, but what we're responsible for, we will be accountable with it and deliver a top line that I think will get us where we need to get. .

Got you. Thank you so much. .

Thank you. One moment while we prepare for our last question. And our last question, we'll be coming from Travis Steed. Travis Steed of Bank of America Securities..

Hey! Thanks for taking the question. Going back to the procedure side, I guess it kind of stands out because other companies are saying things a little bit better, but it sounds like you expect the actual procedure growth to moderate a little bit.

What do you think it is about the mix of your business that's different, and I guess also, are you assuming the second wave? I think that was the, you're assuming a COVID wave again, in the guidance is making sure that was still the case. .

I didn't specifically call out a COVID wave, but I think anybody who's reading materials around health care understands that in the current environment, there's already respiratory disease that is impacting health systems.

There could be you know the typical COVID wave that we've now become accustomed to after a couple of years here in the fall and the seasonal flu, which certainly is on everybody's mind when you – I think somebody actually came up with the term for it, ‘the trifecta viruses this year,’ as we go into the end of the year.

So that could certainly slow down what I would refer to as elective procedures, and by and large the majority of what we do are elective procedures. Now certainly there's some general surgery cases that are not elective, but they can even be delayed.

So I just think we have a mix of businesses that is a little bit more elective in nature, not to say you can put them off, because I think in wave one of COVID it demonstrated that there were co-morbidities associated with delay in surgery broadly speaking, and I think systems have learned that's not a wise move, either for the patient or candidly for their own, for their own workload life balance.

So I – it's just our mix of business is a little bit different than others and you know our third quarter started slow. It picked up as we got into September at a great rate and that was nice to see and we hope that continues into the fourth quarter and gets us to a better spot. .

Okay, good enough, fair enough. On the 300 basic points of inflation Todd, just curious how that's been trending at this point and if the second half gross margin is, it's how we just still think about the jumping off point for next year..

I mean generally, obviously currency got a little worse that's affecting us in Q4 more than we expected three months ago. But I still think that 55 range is probably the right current baseline and then you know the question is, how quickly does inflation improve.

Like Curt said, I'm not sure – you know it hasn't really gotten worse, but it hasn't really gotten a lot better so far in the back half of this year. So we're probably going to have to be a little patient there, so yeah. But I think that that mid-50s is probably the current baseline.

Obviously the acquisitions helped that and as they grow, that's accretive because they are both over 80%, and then AirSeal is in the low 70%, Buffalo Filter is in the low to mid 60%. So all of our growth drivers are accretive to margins, and so as with a little time, that will – we've got a good engine that is driving improving margins.

It's just being masked by the macro challenges that we're facing out there between supply chain and currency. So, at some point – like I said, at some point that cloud will move on and then I think people will feel really good about our margin profile and our growth profile, but you know we're kind of, we're kind of in the clouds right now. .

Thanks for taking the questions. I will follow up offline. Thank you. .

Thanks Travis. .

Thank you. That concludes the Q&A session for today and now I'd like to turn the call back over to Mr. Hartman for closing remarks. .

Thank you, Lisa and I want to thank everybody for your time today and we look forward to speaking with all of you on our next earnings call. Thank you and good night. .

Thank you. This concludes today's conference call. You may all disconnect.

You all have a great evening!.